A MAJOR milestone has been reached with the completion of a new state-of-the-art business facility at the flagship Sci-Tech Daresbury Enterprise Zone.
Practical completion of Techspace One, a three-storey, self-contained building comprising 46,000 sq ft of high quality wet and dry laboratories, grade A office accommodation, meeting hubs and break out areas, took place this week.
The countdown has begun to the official opening of Newcastle University’s Urban Sciences Building which is due to be completed August 2017.
The state-of-the-art structure on Science Central will be the new home for the University’s School of Computing Science and its 1,395 staff and students.
It is the second of the University’s buildings to be completed on the site, following the opening of The Key building in 2015, and has been designed not just as a place for research and learning but as a research experiment itself.
Kent based sterile technology company FutureNova enjoys international success first US sales with plans to scale up manufacturing to meet market demand from the health sector
FutureNova Ltd, backed by the Kent County Council run EXEK equity fund, has made its first successful sales in the United States with plans for a rapid scale up of its Kent based production process following a take-off in overseas demand for its FlipPad® sterile iPad® case.
Fashion meets technology as designers, innovators and business experts come together to create future trends
The fashion industry contributes £26bn to the UK economy, but developments in fashion technology have been far and few between.
Recent innovations mean that consumers can now wear a dress that lights up as it reacts to social media notifications, or shoes that automatically adjust to reduce pressure from tight laces and avoid the wearer slipping if they’re too loose.
OncoMasTR test to launch in 2018 and will reduce the number of patients receiving unnecessary chemotherapy
OncoMark (www.oncomark.com), a University College Dublin (UCD) spin-out company, today announced that is has secured €2.1 million in fundi
UK biotech company Nemaura Pharma has announced a commitment from private investors of up to £5m for the development of a hormone Biologic using its Micro-Patch™ solid dose delivery platform.
£500,000 seed funding by Discovery Park Technology Fund for TC BioPharm builds Kent cluster for immunotherapy research
Last year Discovery Park Technology Fund invested seed-funds in pioneering clinical development company, TC BioPharm (TCB) providing a launchpad for clinical trials of new treatments for cancer and viral infections. This year TCB raised an additional £6.25m series-A fund, cornerstoned by a major pharmaceutical company collaboration.